Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RHOC | P08134 | 1/20 | 0.35 |
| ▸ | RHOA | P61586 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776235 | 0.91 | HCRTR1 (0.48) | HCRTR1HCRTR2ALDH1A1MAPTDPP4 | |
| SCHEMBL6645932 | 0.91 | HCRTR1 (0.48) | HCRTR1HCRTR2ALDH1A1MAPTDPP4 | |
| SCHEMBL1777384 | 0.83 | ALDH1A1 (0.42) | HCRTR1HCRTR2ALDH1A1ACKR3DPP4 | |
| SCHEMBL6641310 | 0.83 | ALDH1A1 (0.42) | HCRTR1HCRTR2ALDH1A1ACKR3DPP4 | |
| SCHEMBL1777409 | 0.79 | HCRTR1 (0.49) | HCRTR1HCRTR2MAPT | |
| SCHEMBL6646483 | 0.77 | RHOC (0.39) | HCRTR1HCRTR2ALDH1A1MAPTDPP4 | |
| SCHEMBL1778081 | 0.77 | RHOC (0.39) | HCRTR1HCRTR2ALDH1A1MAPTDPP4 | |
| SCHEMBL1779433 | 0.76 | L3MBTL1 (0.54) | HPGDHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL1779434 | 0.76 | L3MBTL1 (0.54) | HPGDHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL1776914 | 0.75 | P2RX7 (0.43) | HCRTR1HCRTR2ACKR3MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943645-B2 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. | 2009-03-26 | — | — | US | disclosed |
| US-7423052-B2 | Piperidine compounds for use as orexin receptor antagoinst | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-09-09 | — | — | US | disclosed |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2004-10-28 | — | — | US | disclosed |
| EP-1406897-A2 | COMPOUNDS | SmithKline Beecham plc (GB) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003002559-A2 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | HCRTR2, HCRTR1, OXTR | HPGD 1073/4885HCRTR1 2/4885HCRTR2 1/4885 |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | HCRTR2, HCRTR1, OXTR | HPGD 1534/4885HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.